Trials / Completed
CompletedNCT03776058
Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Clinical Effects of Twice-daily Doses of an Oral Calcimimetic Agent (AMG 073) in Subjects With Primary Hyperparathyroidism (HPT)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives were to assess the safety and tolerability of twice daily (BID) doses of 65 mg cinacalcet administered orally to adults with primary HPT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cinacalcet | Tablets for oral administration |
| DRUG | Placebo | Tablets for oral administration |
Timeline
- Start date
- 2000-06-15
- Primary completion
- 2000-12-26
- Completion
- 2000-12-26
- First posted
- 2018-12-14
- Last updated
- 2018-12-14
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03776058. Inclusion in this directory is not an endorsement.